
EyePoint Pharmaceuticals Investor Relations Material
Latest events

Q2 2025
EyePoint Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from EyePoint Pharmaceuticals Inc
Access all reports
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic therapies. The company specializes in sustained-release drug delivery technologies to address serious eye diseases, including conditions affecting the retina and anterior segment of the eye. EyePoint’s product portfolio includes treatments for inflammation and other ocular disorders, and it supports both commercialized products and clinical development programs. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for EyePoint Pharmaceuticals Inc


Goldman Sachs 46th Annual Global Healthcare Conference
EyePoint Pharmaceuticals Inc


Goldman Sachs 46th Annual Global Healthcare Conference
EyePoint Pharmaceuticals Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
EYPT
Country
🇺🇸 United States